In the past decade, the use of therapeutic antibodies against immune-negative, co-stimulatory molecules, such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), has revolutionized the cancer field. Here, PDCD1 is linked to cancer.